Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study

Abstract

Clinical complete response and negative targeted biopsies left uncertainty regarding pathological clearance. Some patients would trade less aggressive treatment of LM against efficacy.

Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas

“…These reports revealed the immunostimulatory effect of these agonists through effector cells, such as CD8 + T cells, plasmacytoid DCs or M1 macrophages, and decrease the Tregs and MDSC in the tumor lesion, leading to the inhibition of B16F10 melanoma growth in vivo. In addition, more recently, several crinical trial has proved the antitumor effects of IQM against melanoma in situ (34,35). In our present study, we further elucidated the immunomodulatory effect of IQM on TAMs and splenic CD11b + cells during melanoma growth in vivo, especially focusing on the production of Treg-related chemokines and effector T cells-related chemokines.…”

Lymphoedema in patients with lentigo maligna treated with imiquimod: a long-term adverse effect

“…2,3 Complete clinical response rates for LM treated with imiquimod vary from 37Á1% to 100%. [4][5][6] We report three patients with LM who developed lymphoedema following application of topical imiquimod.…”

Challenges of treating melanoma in situ , lentigo maligna type: is pathological clearance the gold standard?

“…In this issue of the BJD , Marsden et al . present one of the few prospective studies (LIMIT‐1) assessing the use of imiquimod for primary treatment of LM, using pathological complete regression (pCR) as a surrogate marker for cure, although clinical complete regression (cCR) was also assessed.…”

“…However, the local‐site reaction can be intense for patients, who may not desire or tolerate months of skin inflammation. In the LIMIT‐1 study, patient preferences were mixed with regard to surgery over imiquimod, based on hypothetical cure rates …”